The weight gain also reflects the lived reality of psychiatric illness
For people living with serious mental illness, obesity is not a side effect to be managed later — it is a compounding crisis that shortens lives through diabetes, heart disease, and cancer. A new analysis of nine clinical trials suggests that semaglutide, a once-weekly injection already reshaping metabolic medicine, may offer meaningful relief to this underserved population, producing roughly sixteen kilograms of weight loss compared to placebo. The finding is preliminary, drawn from fewer than six hundred patients across heterogeneous studies, but it points a direction that researchers and clinicians cannot afford to ignore.
- People with schizophrenia or bipolar disorder gain weight at rates far exceeding the general population, driven by antipsychotic side effects, reduced activity, and the sheer difficulty of self-managing health while managing a serious mental illness.
- A network meta-analysis pooling nine trials found semaglutide outperformed both liraglutide and exenatide on weight loss and key metabolic markers, with no observed increase in psychiatric hospitalizations or symptom worsening.
- The evidence base remains thin — 595 patients total, mostly indirect comparisons, heterogeneous trial designs — leaving researchers unable to confidently rank these medications or establish safe dosing for vulnerable psychiatric populations.
- Gastrointestinal side effects including nausea, vomiting, and constipation were more common with semaglutide and liraglutide, raising real tolerability concerns for a group whose medical care is already complex.
- The field is now pointed toward larger, direct head-to-head randomized trials that must confirm dosing, long-term safety, and sustained effectiveness before semaglutide can become a clinical standard in psychiatric care.
Researchers analyzing nine clinical trials have found that semaglutide appears to outperform other GLP-1 drugs in helping people with serious mental illness lose weight. Pooling data from 595 patients, the analysis — published in Translational Psychiatry — found semaglutide produced roughly 16 kilograms of weight loss compared to placebo, substantially more than liraglutide or exenatide. The authors are careful to frame this as a preliminary signal, not a clinical mandate.
The problem it might address is both real and urgent. People diagnosed with schizophrenia spectrum disorders or bipolar disorder gain weight at rates far exceeding the general population — a consequence of antipsychotic medications like olanzapine and clozapine, reduced physical activity, and the difficulty of managing diet and exercise while managing a serious mental condition. The downstream consequences are severe: type 2 diabetes, cardiovascular disease, certain cancers. This is not a cosmetic concern. It is a medical crisis layered on top of an existing one.
Semaglutide emerged as the clearest performer across weight and metabolic measures, also reducing fasting blood glucose and hemoglobin A1c more substantially than liraglutide. Exenatide showed no statistically significant weight loss at all. Reassuringly, neither semaglutide nor liraglutide was linked to increased psychiatric hospitalizations or worsening symptoms — though both carried higher rates of gastrointestinal side effects including nausea and vomiting.
The authors are explicit about the limits of their conclusions. Nine trials and 595 patients is a small foundation. Most comparisons were indirect, and the trials differed enough in design to complicate interpretation. What the analysis offers is a direction — one that now requires larger, direct, randomized trials to confirm dosing, establish long-term safety, and determine whether this early signal holds up under the scrutiny that clinical adoption demands.
Researchers analyzing nine clinical trials have found that semaglutide, a once-weekly injection, appears to work better than other GLP-1 drugs for helping people with serious mental illness lose weight. The analysis pooled data from 595 patients and found that semaglutide produced roughly 16 kilograms of weight loss compared to placebo—substantially more than liraglutide or exenatide achieved. But the scientists behind the work, published in Translational Psychiatry, are careful to note that the evidence remains preliminary and that larger, more direct comparisons are needed before doctors can confidently rank these medications.
The problem semaglutide might help solve is real and pressing. People diagnosed with schizophrenia spectrum disorders or bipolar disorder gain weight at rates far exceeding the general population. Some of this comes from the medications themselves—antipsychotics like olanzapine and clozapine carry metabolic side effects that pack on pounds. But the weight gain also reflects the lived reality of psychiatric illness: reduced physical activity, diminished motivation, the simple difficulty of managing diet and exercise when managing a serious mental condition. The consequences are severe. Excess weight in this population cascades into type 2 diabetes, cardiovascular disease, certain cancers, and joint damage. It is not a cosmetic problem. It is a medical crisis layered on top of an existing medical crisis.
Traditional weight management—diet and exercise—rarely works well enough on its own for these patients. So researchers have begun testing GLP-1 receptor agonists, a class of drugs originally developed for diabetes that work by mimicking natural metabolic hormones. The question was which one, if any, might be safest and most effective for people whose psychiatric conditions already complicate their medical care.
The network meta-analysis examined three drugs: exenatide (given twice daily or once weekly), liraglutide (once daily), and semaglutide (once weekly). The patient population was predominantly female (55.3 percent) with an average age of 37.8 years, and most had schizophrenia spectrum disorders. Semaglutide emerged as the clear winner on weight and metabolic measures. It lowered body mass index and waist circumference more than the alternatives, and it also reduced fasting blood glucose and hemoglobin A1c—markers of diabetes risk—more substantially than liraglutide. Exenatide showed no statistically significant weight loss compared to placebo.
The side effect profile matters. Both semaglutide and liraglutide caused higher rates of gastrointestinal problems: nausea, vomiting, constipation. These are known risks of the drug class and represent a real tolerability concern. But neither medication was linked to increased psychiatric hospitalizations or worsening psychiatric symptoms, which was reassuring given that any intervention in this population carries the risk of unintended psychiatric consequences.
Yet the authors are explicit about the limits of what they can claim. The evidence base was small—nine trials, 595 people total. The trials were heterogeneous, meaning they differed in design and population in ways that make direct comparison difficult. Most of the comparisons were indirect, meaning researchers were inferring relative effectiveness rather than observing head-to-head results. Before semaglutide can be confidently recommended as the standard treatment for weight management in psychiatric patients, the field needs larger randomized controlled trials that directly compare these drugs, establish safe dosing protocols, and track long-term outcomes in vulnerable populations.
What the analysis does is point a direction. It suggests that semaglutide warrants serious investigation as a tool for addressing one of the most stubborn and consequential health disparities in psychiatry. But it also illustrates the gap between promising preliminary findings and the evidence required to change clinical practice. The next phase of research will determine whether this early signal holds up under scrutiny.
Citações Notáveis
Additional clinical trials are required to establish safe dosages, determine comparative efficacy, and assess long-term outcomes— Study authors
A Conversa do Hearth Outra perspectiva sobre a história
Why does weight gain hit psychiatric patients so much harder than the general population?
It's a perfect storm. The medications that keep people stable—antipsychotics especially—have metabolic side effects built in. Then you layer on the illness itself: reduced motivation, less physical activity, the cognitive load of managing a serious condition. And once the weight starts accumulating, it doesn't just stay as weight. It becomes diabetes, heart disease, cancer risk. It compounds.
So semaglutide showed the best results. What does that actually mean in practical terms?
In these nine trials, people on semaglutide lost about 16 kilograms more than those on placebo. That's real weight loss. The other drugs—liraglutide worked somewhat, exenatide didn't move the needle at all. But here's the thing: we're talking about nine small trials, not one big definitive study.
What's the catch with semaglutide?
Gastrointestinal side effects. Nausea, vomiting, constipation. People have to tolerate that. And we don't have long-term data yet. We don't know if it stays effective, if new problems emerge, if it interacts badly with psychiatric medications in ways we haven't seen yet.
The researchers seem cautious. Why?
Because they're being honest about what the evidence actually shows. They pooled nine trials—that's not a lot. The trials were different from each other in important ways. Most of the comparisons weren't direct; they were inferred. You can't tell a patient this is definitely the best option when the evidence is still that preliminary.
What happens next?
Larger head-to-head trials. Real comparison studies. Longer follow-up. Dosing protocols. Safety monitoring in psychiatric populations specifically. This is the beginning of the conversation, not the end of it.